Overview: NGS MODY Disease Sequencing TestIntroduction: The NGS MODY Disease Sequencing Test sequences genes to diagnose maturity-onset diabetes of the young (MODY), causing early-onset diabetes. Following 2023 ADA guidelines, it uses PCR for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected MODY.
Other Names: MODY NGS Assay, HNF1A/GCK Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: MODY sequencing began in the 1990s with diabetes genetic research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose MODY, guides treatment, and evaluates patients with early-onset diabetes.
Test Parameters: 1. MODY Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of early-onset diabetes, hyperglycemia, or MODY symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document early-onset diabetes, hyperglycemia, or family history of MODY. Include current medications, especially insulin or sulfonylureas.
Consent: Written consent required, detailing the tests purpose, MODY implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze MODY genes (e.g., HNF1A, GCK). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for MODY diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm MODY, guiding sulfonylurea therapy or genetic counseling. Negative results may require HbA1c testing.
Specialist Consultation: Consult an endocrinologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: HbA1c, fasting glucose, or C-peptide levels to confirm MODY diagnosis.
Test Limitations: Not all MODY cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: ADA MODY Guidelines, 2023; Diabetes Care, Hattersley AT, 2022.
